Jazz Pharmaceuticals has signed a definitive agreement to acquire Redx Pharma’s pan-RAF inhibitor program for the potential treatment of RAF and RAS mutant tumors. Redx will perform certain preclinical activities for the program under a separate collaboration with Jazz. Jazz will be responsible for further development, regulatory activities and commercialization.   Jazz will pay Redx an upfront payment of $3.5 million. Redx is eligible to receive up to $203 million in development, regula...